Adtalem Global Education Inc.

Adtalem Global Education Inc. (ATGE) Market Cap

Adtalem Global Education Inc. has a market capitalization of $3.87B.

Financials based on reported quarter end 2025-12-31

Price: $106.64

1.57 (1.49%)

Market Cap: 3.87B

NYSE · time unavailable

CEO: Stephen W. Beard

Sector: Consumer Defensive

Industry: Education & Training Services

IPO Date: 1991-06-21

Website: https://www.adtalem.com

Adtalem Global Education Inc. (ATGE) - Company Information

Market Cap: 3.87B · Sector: Consumer Defensive

Adtalem Global Education Inc. provides workforce solutions worldwide. It operates through three segments, Chamberlain, Walden, and Medical and Veterinary. The Chamberlain segment offers degree and non-degree programs in the nursing and health professions postsecondary education industry. This segment operates Chamberlain University. The Walden segment offers online certificates, bachelor's, master's, and doctoral degrees, including nursing, education, counseling, business, psychology, public health, social work and human services, public administration and public policy, and criminal justice. This segment also operates Walden University. The Medical and Veterinary segment provides degree and non-degree programs in the medical and veterinary postsecondary education industry. This segment operates American University of the Caribbean School of Medicine, Ross University School of Medicine, and Ross University School of Veterinary Medicine. The company was formerly known as DeVry Education Group Inc. and changed its name to Adtalem Global Education Inc. in May 2017. Adtalem Global Education Inc. was incorporated in 1987 and is based in Chicago, Illinois.

Analyst Sentiment

92%
Strong Buy

Based on 2 ratings

Analyst 1Y Forecast: $155.80

Average target (based on 3 sources)

Consensus Price Target

Low

$138

Median

$151

High

$163

Average

$151

Potential Upside: 41.1%

Price & Moving Averages

Loading chart...

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 ADTALEM GLOBAL EDUCATION INC (ATGE) — Investment Overview

🧩 Business Model Overview

Adtalem Global Education Inc (NYSE: ATGE) operates as a leading provider of post-secondary education, primarily serving the healthcare, medical, and professional education markets. The company delivers a portfolio of educational programs through a combination of physical campuses and digital learning platforms. Core brands include Chamberlain University, American University of the Caribbean School of Medicine, Ross University School of Medicine, Ross University School of Veterinary Medicine, and Walden University. These institutions offer undergraduate, graduate, and professional degrees across nursing, medical, veterinary, and other life sciences disciplines. Adtalem’s approach is centered on equipping adult learners with career-focused education tailored to high-demand industries. The company’s business model combines tuition-based revenue with strong student support services, licensure exam preparation, and tailored curricula designed to maximize graduate employability. By focusing on healthcare education—a segment characterized by steady demand and regulatory/credentialing intensity—Adtalem aims to differentiate itself from broader for-profit peers.

💰 Revenue Streams & Monetisation Model

Adtalem primarily generates revenue through tuition and fees paid by students enrolled in its educational programs. The substantial majority of revenues originate from medical and healthcare education, where programs are typically multi-year and command premium tuition rates. Additional sources include fees from student services, examination and licensing prep, and online course delivery. Various institutions within the Adtalem portfolio are eligible for Title IV federal financial aid in the United States, ensuring access for a wide pool of students and underpinning enrollment stability. The company’s online-enabled programs, particularly through Walden University and Chamberlain Online, have further diversified the revenue base. Income from continuing professional education, certification prep, and upskilling/career advancement products represent additional monetization opportunities, albeit as a smaller slice of the overall mix. Overall, the predictability and recurring nature of healthcare education tuition serve as a stabilizing factor in revenue generation.

🧠 Competitive Advantages & Market Positioning

Adtalem’s differentiated market position stems from several key competitive advantages: - **Specialization in Healthcare Education:** With a deep focus on healthcare, nursing, and veterinary science, Adtalem has developed domain expertise, strong academic reputation, and relationships with leading clinical partners and health systems. This domain focus supports above-average student outcomes and strong employment rates for graduates. - **Accredited Programs & Regulatory Compliance:** The company’s educational institutions are regionally accredited and often hold further discipline-specific accreditations. This status is vital for attracting students, accessing financial aid, and maintaining credibility with licensing bodies. - **Hybrid Delivery Model:** Adtalem offers flexible education through a blend of physical campuses, clinical placements, and scalable online platforms. This flexibility supports increasing enrollment and geographic reach. - **Brand Portfolios with Established Track Records:** Chamberlain University and Walden University, in particular, have recognized brands, alumni networks, and institutional relationships that help attract a steady flow of students. - **Operational Scale:** The company’s size allows for efficiencies in marketing, technology investment, regulatory management, and the ability to evolve curricula based on healthcare trends and employer needs.

🚀 Multi-Year Growth Drivers

Several structural growth drivers underpin Adtalem’s long-term potential: - **Increasing Demand for Healthcare Professionals:** Demographic shifts, such as aging populations and expanded access to healthcare, are driving strong and persistent demand for nurses, physicians, healthcare administrators, and allied health professionals. This growing need supports robust enrollment pipelines for Adtalem’s core programs. - **Growing Adoption of Online and Hybrid Education:** Student preferences and employer acceptance of online credentials continue to rise. Adtalem’s established digital platforms position it well to capture market share and reduce per-capita delivery costs. - **Workforce Development & Upskilling:** Ongoing medical innovation and evolving standards of care are increasing the need for continuing education, certifications, and reskilling—areas where Adtalem’s programs and partnerships provide growth runway. - **International Expansion Opportunities:** Select programs, such as Ross University School of Medicine in the Caribbean, provide geographic diversification and access to international students seeking U.S.-relevant credentials. - **Strategic Acquisitions and Program Expansion:** The company has a track record of expanding its portfolio through disciplined M&A, product innovation, and investing in adjacent healthcare verticals.

⚠ Risk Factors to Monitor

Investors should be aware of several key risks: - **Regulatory and Legislative Exposure:** Adtalem, like all for-profit and vocational educators, operates under intense regulatory scrutiny in the U.S. Changes in Title IV regulations, gainful employment standards, or accreditation could materially impact revenue eligibility and operational flexibility. - **Enrollment Volatility:** Shifts in student demand due to macroeconomic factors, competition, or perceived ROI of degrees may affect enrollment levels and revenue visibility. - **Exposure to Student Outcomes:** Adtalem’s institutions rely on maintaining strong licensure exam pass rates and employment outcomes. Underperformance impacts reputation, accreditations, and could trigger regulatory intervention. - **Competition:** Other for-profit and not-for-profit educational institutions continue to increase offerings in healthcare fields, intensifying competition for students. - **Reputation Management:** Issues related to tuition pricing, student debt, marketing practices, or graduate employability can generate negative publicity and potential legal or regulatory challenges. - **Execution Risks on Program Expansion:** New program launches or acquisitions carry integration and execution risks, particularly if misalignment with market needs occurs.

📊 Valuation & Market View

Adtalem’s equity is generally evaluated as a specialized education services provider with differentiated exposure to resilient, regulatory-driven healthcare education markets. The company tends to command valuation premiums relative to broader for-profit education peers, largely given the recurring nature of healthcare-professional demand, ownership of accredited institutes, and strong graduate outcomes. Discounted cash flow models for Adtalem are typically anchored by stable enrollment, healthy operating margins, and moderate organic growth forecasts, balanced against regulatory and cost risks. Multi-year multiples such as EV/EBITDA or P/E ratios trend higher than smaller, non-healthcare focused education names, justified by the company’s scale, brand reputation, and strategic position in a highly credentialed and credential-dependent field. The investment community often benchmarks Adtalem’s performance and outlook relative to nursing, medical school, and online education peers, as well as broader themes in workforce development and healthcare infrastructure.

🔍 Investment Takeaway

Adtalem Global Education Inc represents a well-positioned and scalable platform uniquely focused on the nexus of education and healthcare workforce development. Its durable business model, driven by domain specialization, accreditations, and flexible delivery modalities, caters directly to secular tailwinds in healthcare demand. The combination of established brands, regulatory compliance, and digital transformation provides the company with both resilience and operational leverage. That said, prospective investors should weigh significant regulatory risks and exposure to student outcomes, both of which remain outsized for the sector. Execution on growth initiatives and continued enhancement of student value proposition will be important for sustaining long-term value creation. Adtalem stands out as a differentiated operator with the scale and brand strength to compete effectively, offering the potential for durable and compounding shareholder returns, contingent on disciplined management of sector-specific headwinds.

⚠ AI-generated — informational only. Validate using filings before investing.

Fundamentals Overview

Loading fundamentals overview...

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"For the fiscal year ending December 31, 2025, ATGE reported revenue of $503.4M and a net income of $76.4M, translating to an EPS of $2.11. Operating cash flow stood at $29.7M, with a free cash flow of $15.1M following capital expenditures of $14.6M. The total assets are valued at approximately $2.61B against total liabilities of $1.24B, resulting in total equity of about $1.38B. The company's leverage, indicated by a net debt of $673.3M, is manageable in relation to the equity base. Over the past year, ATGE's stock price has appreciated by 7.85%, which, coupled with a lack of dividends, indicates moderate shareholder returns. Analyst sentiment shows a consensus price target of $157, reflecting potential upside from the current price of $106.49, although the stock has experienced a notable decline over the past six months. Overall, while ATGE shows positive revenue and profitability metrics, its moderate price change suggests cautious sentiment in the current market."

Revenue Growth

Positive

Strong revenue growth observed with $503.4M reported.

Profitability

Neutral

Net income of $76.4M signifies decent profitability.

Cash Flow Quality

Fair

Operating cash flow positive but limited free cash flow.

Leverage & Balance Sheet

Positive

Debt levels are manageable relative to equity.

Shareholder Returns

Caution

7.85% price gain in 1 year, no dividends paid.

Analyst Sentiment & Valuation

Neutral

Consensus price target suggesting potential upside.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Management delivered strong Q2 profitability and raised EPS despite a known near-term enrollment timing issue. Headline results were strong: revenue +12.4% to $503.4M, adjusted EBITDA margin expanded 290 bps to 30.8% (with a large portion excluding a $18M one-week Walden calendar shift), and adjusted EPS rose 34.3% to $2.43. They reiterated revenue guidance but lifted full-year adjusted EPS to $7.80–$8.00 (midpoint +$0.15), citing ~100 bps FY adjusted EBITDA margin expansion and cash-flow strength. However, the Q&A pressures centered on Chamberlain’s soft/flat enrollment path: management admitted total enrollment should remain flat in the second half and that improvements are primarily in double-digit applications and fall-cycle recovery, not immediate revenue. For exceeding the high-end EPS guide, they pointed to a faster-than-expected Chamberlain recovery and/or MedVet acceleration—implicitly acknowledging execution risk remains tied to the fall cycle rather than already realized enrollment gains.

AI IconGrowth Catalysts

  • Walden: tenth consecutive quarter of enrollment growth; +13% total enrollment in Q2 (to 52,400) and new program traction (M.A. in applied behavioral analysis and M.S. in clinical psychology; 1,002+ enrolled in <1 year)
  • Walden: operational excellence and leverage; adjusted EBITDA margin expansion driven by efficiencies outpacing increased brand/digital investments
  • Chamberlain: application volumes up double digits in Q2 after addressing prior execution gaps (marketing effectiveness and enrollment funnel conversion)
  • MedVet: near-capacity operations; continued improvement in NAVLE pass rate; incremental enrollment pathway initiatives
  • Medical schools: technology/AI in basic sciences and capstone program driving improved USMLE Step 1 pass rates

Business Development

  • Sallie Mae: partnership update—definitive documentation in progress and capital syndicate being assembled; expected use of supplemental lending sources around anticipated loan cap changes in July

AI IconFinancial Highlights

  • Revenue: +12.4% to $503.4M; excluding the one-week academic calendar shift, revenue up 8.4%
  • One-week calendar shift: $18M revenue recognized in Q2 instead of Q3 (pronounced for Walden, reduces Q3 revenue by comparison; no net annual impact)
  • Adjusted EBITDA: $154.9M, +23.9% YoY
  • Adjusted EBITDA margin: 30.8% expanded 290 bps YoY; excluding the one-week shift, margin up 30 bps YoY
  • Adjusted EPS: $2.43, +34.3% YoY
  • Q2 capital return: repurchased 1.7M shares at avg $95; completed $150M authorization
  • Full-year revenue guidance reiterated: $1.90B–$1.94B (~6%–8.5% YoY)
  • Full-year adjusted EPS guidance raised to $7.80–$8.00 (growth 17%–20%); prior range lifted from $7.60–$7.90 (growth 14%–18.5%)—midpoint increase of +$0.15
  • EPS guidance raise rationale: commitment to expanding FY26 adjusted EBITDA margin by ~100 bps
  • Tax: effective tax rate expected higher than FY2025

AI IconCapital Funding

  • Share repurchases deployed in Q2: $165M; completed prior $150M authorization
  • New board authorization: $750M through Dec 2028; $728M available as of Dec 31
  • Trailing twelve months operating cash flow: $428M, +$146M YoY

AI IconStrategy & Ops

  • Chamberlain: actions taken to close two execution gaps—marketing effectiveness and enrollment funnel conversion; also made personnel changes
  • Chamberlain: optimized marketing spend, improved website, streamlined scholarship offerings to improve net cost clarity
  • Walden: continued digital platform/flexible offerings; streamlined professional doctoral programs and launched PhD completion program for students who left before dissertation completion
  • Walden: margin benefit despite higher brand/student-facing digital investments; additional student support commensurate with enrollment growth
  • Capital allocation: disciplined, returns-focused approach; balance between growth investments and scaled operational foundation
  • Margin seasonality disclosed: FY26 quarter-to-quarter margin volatility expected (more targeted investments in Q3; less in Q4); one-week Walden shift impacts Q3 margin profile

AI IconMarket Outlook

  • Chamberlain enrollment outlook: Q3 total enrollment expected soft/flat; despite improving applications, management expects quarterly total enrollment to be flat over the balance of FY
  • Inflection timing: management expects recovery to show as approach fall enrollment cycle; exit FY moving toward positive total enrollment growth at Chamberlain
  • MedVet upside case for exceeding EPS: quicker return to form at Chamberlain and/or additional acceleration at MedVet
  • Investor Day: February 24 (multiyear growth framework, capacity expansion plans, new revenue streams)

AI IconRisks & Headwinds

  • Chamberlain: near-term enrollment softness/flatness—management attributes to a temporary pause (not a reversal), but emphasized need to 'dig out' given fall cycle is largest cycle
  • Chamberlain: financial impact of application improvements is not immediate—application growth expected to translate to later quarters' enrollment growth
  • Loan cap regulatory change (July): potential financing constraint risk; mitigation underway via Sallie Mae partnership and use of supplemental lending sources
  • Tax headwind: effective tax rate expected higher than FY2025
  • Margin pressure risk: higher targeted investments in Q3 and one-week calendar shift impacting Q3 margin profile

Sentiment: MIXED

Note: This summary was synthesized by AI from the ATGE Q2 2026 (ended prior to 2026-01-28) earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
📁

SEC Filings (ATGE)

© 2026 Stock Market Info — Adtalem Global Education Inc. (ATGE) Financial Profile